Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $10,864.00 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 679 shares of the firm’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $16.00, for a total value of $10,864.00. Following the completion of the transaction, the insider owned 3,622 shares in the company, valued at $57,952. The trade was a 15.79% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, March 16th, Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock opened at $17.76 on Monday. The company has a fifty day simple moving average of $15.54 and a 200-day simple moving average of $16.04. The firm has a market capitalization of $404.75 million, a price-to-earnings ratio of -3.10 and a beta of 0.93. Avalo Therapeutics, Inc. has a 52-week low of $3.39 and a 52-week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $1.17. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of ($0.21) million. On average, research analysts anticipate that Avalo Therapeutics, Inc. will post -19.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AVTX shares. BTIG Research restated a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a report on Tuesday, March 24th. Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. Guggenheim started coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Finally, HC Wainwright upped their target price on Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Avalo Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $42.25.

Institutional Trading of Avalo Therapeutics

Hedge funds have recently made changes to their positions in the business. Orbimed Advisors LLC grew its holdings in shares of Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after purchasing an additional 382,300 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in Avalo Therapeutics by 24.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after buying an additional 240,000 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in Avalo Therapeutics by 4.5% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company’s stock worth $19,087,000 after buying an additional 44,837 shares in the last quarter. Caligan Partners LP boosted its position in Avalo Therapeutics by 5.8% in the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock valued at $16,009,000 after buying an additional 48,200 shares during the period. Finally, Balyasny Asset Management L.P. purchased a new position in Avalo Therapeutics in the 3rd quarter valued at approximately $10,390,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.